sapanisertib
Selected indexed studies
- Sapanisertib attenuates pulmonary fibrosis by modulating Wnt5a/mTOR signalling. (Basic Clin Pharmacol Toxicol, 2023) [PMID:37394756]
- Repurposing sapanisertib in malaria. (Nat Rev Drug Discov, 2022) [PMID:36323854]
- Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. (NPJ Precis Oncol, 2023) [PMID:37072571]
_Worker-drafted node — pending editorial review._
Connections
sapanisertib is a side effect of
Sources
- Sapanisertib attenuates pulmonary fibrosis by modulating Wnt5a/mTOR signalling. (2023) pubmed
- Repurposing sapanisertib in malaria. (2022) pubmed
- Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. (2023) pubmed
- Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. (2022) pubmed
- Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. (2024) pubmed
- The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages. (2022) pubmed
- Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. (2021) pubmed
- Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidylinositol 4-Kinase Beta and cGMP-Dependent Protein Kinase Inhibitor, for Malaria. (2025) pubmed
- Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. (2024) pubmed
- A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. (2022) pubmed